Amicus Therapeutics

Unlock to Claim this listing
Add / Modify Company

Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. Unlike other treatments which replace defective enzymes, Amicus uses small molecule pharmacological “chaperones” which bind to a patient’s own defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease. Another candidate, Plicera, is in development to treat Gaucher disease, while a third candidate, AT2220 is targeting Pompe disease. The company is also researching treatments for neurodegenerative diseases including Alzheimer’s and Parkinson’s.

Click to rate this company
[Total: 0 Average: 0]

3.2

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

Amicus Therapeutics demonstrates a commitment to environmental sustainability by integrating responsible practices into its operations. While the primary focus is on developing innovative therapies for rare diseases, the company may implement eco-friendly practices and technologies within its facilities. Energy-efficient laboratory practices, waste reduction measures, and responsible sourcing for materials are potential ways in which Amicus Therapeutics can minimize its ecological footprint and contribute to environmental conservation.Amicus Therapeutics’ social impact is significant, driven by its mission to provide treatments for individuals with rare and devastating diseases. The company’s therapies have the potential to positively impact patient outcomes, improve quality of life, and address unmet medical needs. Amicus Therapeutics’ dedication to social impact aligns with its efforts to enhance patient care and contribute to better health outcomes globally.Amicus Therapeutics’ operations, reflecting its commitment to transparency, regulatory compliance, and responsible drug development. The company’s leadership emphasizes ethical conduct, patient safety, and research integrity, building trust with regulators, partners, and patients. Amicus Therapeutics’ robust governance framework ensures that ethical standards are upheld throughout its drug development and research processes.Amicus Therapeutics recognizes the interplay between responsible practices and sustained financial growth. The company’s financial strategy integrates sustainability considerations, contributing to long-term value creation for patients, partners, and investors. Amicus Therapeutics’ approach to risk management and financial stability is aligned with its commitment to delivering innovative therapies that positively impact patient care.The company’s focus on providing safe, effective, and ethical therapies underscores its dedication to improving patient health outcomes. Amicus Therapeutics’ emphasis on ethical behavior extends to its collaborations with healthcare professionals, regulatory bodies, and stakeholders, ensuring that its therapies positively impact patient well-being while maintaining the highest standards of integrity.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$329,200,000.00

Website Traffic

Employee Rating

3.1

Customer Rating

3.8

Company Size

100-1000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.